Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
复制标题
DOI：
10.1038/s41467-023-36561-6
复制
发表时间：
2023-02-14
影响因子：
16.6
通讯作者：
Schwartz, Olivier
中科院分区：
文献类型：
--
作者：
Planas, Delphine;Bruel, Timothee;Staropoli, Isabelle;Guivel-Benhassine, Florence;Porrot, Francoise;Maes, Piet;Grzelak, Ludivine;Prot, Matthieu;Mougari, Said;Planchais, Cyril;Puech, Julien;Saliba, Madelina;Sahraoui, Riwan;Femy, Florent;Morel, Nathalie;Dufloo, Jeremy;Sanjuan, Rafael;Mouquet, Hugo;Andre, Emmanuel;Hocqueloux, Laurent;Simon-Loriere, Etienne;Veyer, David;Prazuck, Thierry;Pere, Helene;Schwartz, Olivier
SARS-CoV-2 Omicron BA.2、BA.4和BA.5谱系的趋同进化导致了几个新的亚变体的出现，包括BA.2.75.2和BA.4.6。和BQ.1.1。亚变体BQ.1.1于2022年12月在许多国家占主导地位。这些亚变异体在突刺中携带了一组额外的、通常是冗余的突变，可能是增加传播性和免疫逃避的原因。在这里，我们建立了一个病毒扩增程序，以方便地分离欧米克隆菌株。我们检测了它们对6种治疗性单克隆抗体（mab）的敏感性，以及对辉瑞bnt162b2疫苗接种个体的72份血清（含或不含BA.1/BA）的敏感性。2或ba5突破感染。Ronapreve （Casirivimab和Imdevimab）和Evusheld （Cilgavimab和Tixagevimab）对BA.2.75.2和BQ.1.1失去抗病毒效果，而Xevudy （Sotrovimab）仍然具有弱活性。BQ.1.1对Bebtelovimab也有耐药性。接种三次疫苗的个体在增强后4个月对bq1.1和ba2.75.2的中和效价低至无法检测。BA.1 / BA。2型突破感染增加了这些滴度，与BA.2.75.2和BQ.1.1相比，其滴度仍低约18倍。相反，BA.5突破感染对BA.5和BQ.1.1的中和作用比对BA.2.75.2的中和作用更有效。因此，新的Omicron亚变体的进化轨迹促进了它们在免疫人群中的传播，并引起了对大多数可用单克隆抗体有效性的关注。在这项研究中，Planas等人报道了Omicron亚变体BA.2.75.2、BA.4.6和BQ.1.1逃避了单克隆抗体的中和作用，接种了或未接种Omicron BA.1/2或BA.5突破感染的个体的血清。
Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariant BQ.1.1 became predominant in many countries in December 2022. The subvariants carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and Imdevimab) and Evusheld (Cilgavimab and Tixagevimab) lose antiviral efficacy against BA.2.75.2 and BQ.1.1, whereas Xevudy (Sotrovimab) remaine weakly active. BQ.1.1 is also resistant to Bebtelovimab. Neutralizing titers in triply vaccinated individuals are low to undetectable against BQ.1.1 and BA.2.75.2, 4 months after boosting. A BA.1/BA.2 breakthrough infection increases these titers, which remains about 18-fold lower against BA.2.75.2 and BQ.1.1, than against BA.1. Reciprocally, a BA.5 breakthrough infection increases more efficiently neutralization against BA.5 and BQ.1.1 than against BA.2.75.2. Thus, the evolution trajectory of novel Omicron subvariants facilitates their spread in immunized populations and raises concerns about the efficacy of most available mAbs. In this work, Planas et al. report that Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 escape neutralization from monoclonal antibodies, and sera from vaccinated individuals with or without Omicron BA.1/2 or BA.5 breakthrough infection.
登录
查看更多内容
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
影响因子：
64.8
作者：
Cao, Yunlong;Yisimayi, Ayijiang;Jian, Fanchong;Song, Weiliang;Xiao, Tianhe;Wang, Lei;Du, Shuo;Wang, Jing;Li, Qianqian;Chen, Xiaosu;Yu, Yuanling;Wang, Peng;Zhang, Zhiying;Liu, Pulan;An, Ran;Hao, Xiaohua;Wang, Yao;Feng, Rui;Sun, Haiyan;Zhao, Lijuan;Zhang, Wen;Zhao, Dong;Zheng, Jiang;Yu, Lingling;Li, Can;Zhang, Na;Wang, Rui;Niu, Xiao;Yang, Sijie;Song, Xuetao;Chai, Yangyang;Hu, Ye;Shi, Yansong;Zheng, Linlin;Li, Zhiqiang;Gu, Qingqing;Shao, Fei;Huang, Weijin;Jin, Ronghua;Shen, Zhongyang;Wang, Youchun;Wang, Xiangxi;Xiao, Junyu;Xie, Xiaoliang Sunney
通讯作者：
Xie, Xiaoliang Sunney
通过遗传距离分析快速评估 COVID-19 疫苗针对 SARS-CoV-2 变体症状感染的有效性
影响因子：
82.9
作者：
Cao, Lirong;Lou, Jingzhi;Chan, See Yeung;Zheng, Hong;Liu, Caiqi;Zhao, Shi;Li, Qi;Mok, Chris Ka Pun;Chan, Renee Wan Yi;Chong, Marc Ka Chun;Wu, William Ka Kei;Chen, Zigui;Wong, Eliza Lai Yi;Chan, Paul Kay Sheung;Zee, Benny Chung Ying;Yeoh, Eng Kiong;Wang, Maggie Haitian
通讯作者：
Wang, Maggie Haitian
影响因子：
32.4
作者：
Gruell, Henning;Vanshylla, Kanika;Weber, Timm;Barnes, Christopher O.;Kreer, Christoph;Klein, Florian
通讯作者：
Klein, Florian
影响因子：
64.8
作者：
Carreno, Juan Manuel;Alshammary, Hala;Krammer, Florian
通讯作者：
Krammer, Florian